Stroke prevention: From available antiplatelet drugs to novel molecular targets

Current Drug Targets

Volumn 14, Issue 1, 2013, Pages 3-12

  Di Minno, Matteo Nicola Dario ^a   Momi, Stefania ^b   Di Minno, Alessandro ^a   Russolillo, Anna ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b UNIVERSITY OF PERUGIA   (Italy)

Author keywords

Limitation of current therapies; Molecular targets; New antiplatelet drugs; New perspectives; Prevention strategies; Stroke

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; AJW 200; ALTEPLASE; ALX 0081; ANTI VON WILLEBRAND FACTOR NANOBODY; ANTITHROMBOCYTIC AGENT; ATOPAXAR; AZD 6482; CANGRELOR; CILOSTAZOL; CLOPIDOGREL; DELCASERTIB; DIPYRIDAMOLE; DZ 697B; EGAPTIVON PEGOL; ELINOGREL; FOSTAMATINIB; HEPARIN; PLACEBO; PRASUGREL; REVACEPT; SARPOGRELATE; TG 100 115; TICAGRELOR; TICLOPIDINE; TIROFIBAN; UNCLASSIFIED DRUG; VON WILLEBRAND FACTOR; VORAPAXAR;

BLEEDING; BRAIN HEMORRHAGE; CEREBROVASCULAR ACCIDENT; DISEASE ASSOCIATION; DNA POLYMORPHISM; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; GASTROINTESTINAL DISEASE; GASTROINTESTINAL HEMORRHAGE; HEMATOLOGIC DISEASE; HUMAN; INCIDENCE; INTRACELLULAR SIGNALING; LIVER DYSFUNCTION; LOW DRUG DOSE; META ANALYSIS (TOPIC); MULTICENTER STUDY (TOPIC); NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); QT PROLONGATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENT DISEASE; REFRACTORY THROMBOCYTOPENIA; REVIEW; RISK FACTOR; THROMBOCYTE COUNT; THROMBOSIS; THROMBOTIC THROMBOCYTOPENIC PURPURA; TRANSIENT ISCHEMIC ATTACK;

EID: 84876730881     PISSN: 13894501     EISSN: 18735592     Source Type: Journal    
DOI: 10.2174/138945013804806488     Document Type: Review

References (100)

1. Di Minno MND, Russolillo A, Camera M, et al. New Anti-Thrombotic Drugs for Stroke Prevention. Curr Vasc Pharmacol 2011; 104: 664-80.
2. Hankey GJ. Long-term outcome after ischaemic stroke/transient ischaemic attack. Cerebrovasc Dis 2003; 16(Suppl 1): 14-9.
3. Gensini GF, Zaninelli A, Bignamini AA, et al. SPREAD-Stroke, Prevention and Educational Awareness Diffusion. Italian guidelines for prevention and treatment, January 2010, VI ed. Italy: Publications Catel-Hyperphar Group SpA. Available from http:// www.spread.it/node/60.
4. Meadows TA, Bhatt DL. Clinical aspects of platelet inhibitors and thrombus formation. Circ Res 2007; 100: 1261-75.
5. Antithrombotic Trialists' Collaboration. Collaborative metaanalysis of randomized trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002; 324: 71-86.
6. Baigent C, Blackwell L, Collins R, et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative metaanalysis of individual participant data from randomised trials. Lancet. 2009; 373(9678): 1849-60.
7. Gent M, Easton JD, Ellis DJ, et al. The Canadian American Ticlopidine Study (CATS) in thromboembolic stroke. Lancet 1989; 19: 442-3.
8. Hass WK, Easton DJ, Adams HP, et al. A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients: Ticlopidine Aspirin Stroke Study Group. N Engl J Med 1989; 321: 501-7.
9. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996; 348: 1329-39.
10. Bhatt DL, Flather MD, Hacke W, et al. Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial. J Am Coll Cardiol 2007; 49: 1982-8.
11. Angiolillo DJ, Guzman LA, Bass TA. Current antiplatelet therapies: benefits and limitations. Am Heart J 2008; 156(Suppl 2): S3-S9.
12. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, et al. Variability in individual responsiveness to clopidogrel: clinical implications, management, and future perspectives. J Am Coll Cardiol 2007; 49: 1505-16.
13. Krasopoulos G, Brister SJ, Beattie WS, et al. Aspirin "resistance" and risk of cardiovascular morbidity: systematic review and metaanalysis. BMJ 2008; 336: 195-98.
14. Mason PJ, Jacobs AK, Freedman JE. Aspirin resistance and atherothrombotic disease. J Am Coll Cardiol 2005; 46: 986-93.
15. Russolillo A, Di Minno MND, Tufano A, et al. Filling the gap between science & clinical practice: Prevention of stroke recurrence. Thromb Res 2012; 129: 3-8.
16. Angiolillo DJ. Variability in responsiveness to oral antiplatelet therapy. Am J Cardiol 2009; 103(3 Suppl): 27A-34A.
17. Sofi F, Marcucci AR, Gori AM, et al. Clopidogrel nonresponsiveness and risk of cardiovascular morbidity. An updated metanalysis. Thromb Haemost 2010; 103: 841-8.
18. Maree AO, Curtin RJ, Chubb A, et al. Cycloxygenase-1 haplotype modulates platelet response to aspirin. J Thromb Haemost 2005; 3: 2340-5.
19. Mega JL, Close SL, Wiviott SD, et al. Cytochrome p-450 polymorphisms and response to clopidogrel. N Engl J Med 2009; 360: 354-62.
20. Tabassome S, Verstuyft C, Mary-Krause M, et al. Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med 2009; 360: 363-75.
21. Motovska Z, Widimsky P, Kvasnicka J, et al. High loading dose of clopidogrel is unable to satisfactorily inhibit platelet reactivity in patients with glycoprotein IIIA gene polymorphism: a genetic substudy of PRAGUE-8 trial. Blood Coagul Fibrinolysis 2009; 20: 257-62.
22. Di Minno MN, Lupoli R, Palmieri NM, et al. Aspirin resistance, platelet turnover, and diabetic angiopathy: a 2011 update. Thromb Res 2012; 129: 341-4.
23. Di Minno MND, Guida A, Camera M, et al. Overcoming limitations of current antiplatelet drugs: A concerted effort for more profitable strategies of intervention. Ann Med 2011; 43: 531-44.
24. Gresele P, Momi S, Falcinelli E. Anti-platelet therapy: phosphodiesterase inhibitors. Br J Clin Pharmacol 2011; 72: 634-46.
25. Shrör K. The pharmacology of cilostazol. Diabetes Obes Metab 2002; 4 (Suppl 2): S14-9.
26. Gotoh F, Tohgi H, Hirai S, et al. Cilostazol Stroke Prevention Study: a placebo-controlled double-blind trial for secondary prevention of cerebral infarction. J Stroke Cerebrovasc Dis 2000; 9: 147-57.
27. Shinohara Y, Katayama Y, Uchiyama S, et al. CSPS 2 group. Cilostazol for prevention of secondary stroke (CSPS 2): an aspirincontrolled, double-blind, randomised non-inferiority trial. Lancet Neurol 2010; 90: 959-68.
28. Uchiyama S, Demaerschalk BM, Goto S, et al. Stroke prevention by cilostazol in patients with atherothrombosis: meta-analysis of placebo-controlled randomized trials. J Stroke Cerebrovasc Dis 2009; 18: 482-90.
29. Diener HC, Cunha L, Forbes C, et al. European Stroke Prevention Study 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J Neurol Sci 1996; 143: 1-13.
30. Halkes PH, van Gijn J, Kappelle LJ, et al. ESPRIT Study Group. Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): randomised controlled trial. Lancet 2006; 367: 1665-73.
31. Verro P, Gorelick PB, Nguyen D. Aspirin plus dipyridamole versus aspirin for prevention of vascular events after stroke or TIA: a meta-analysis. Stroke 2008; 39: 1358-63.
32. Sacco RL, Diener HC, Yusuf S, et al. PRoFESS Study Group. Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke. N Engl J Med 2008; 359: 1238-51.
33. Wiviott SD, Antman EM, Gibson CM, et al. Evaluation of prasugrel compared with clopidogrel in patients with acute coronary syndromes: design and rationale for the TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet InhibitioN with prasugrel Thrombolysis In Myocardial Infarction 38 (TRITON-TIMI 38). Am Heart J 2006; 152: 627-35.
34. James S, Akerblom A, Cannon CP, et al. Comparison of ticagrelor, the first reversible oral P2Y (12) receptor antagonist, with clopidogrel in patients with acute coronary syndromes: rationale, design, and baseline characteristics of the PLATelet inhibition and patient Outcomes (PLATO) trial. Am Heart J 2009; 157: 599-605.
35. Angiolillo DJ, Firstenberg MS, Price MJ, et al; (BRIDGE Investigators). Bridging antiplatelet therapy with cangrelor in patients undergoing cardiac surgery: a randomized controlled trial. JAMA 2012; 307: 265-74.
36. Welsh RC, Rao SV, Zeymer U, et al. on behalf of the INNOVATEPCI Investigators. A Randomized, Double-Blind, Active-Controlled Phase 2 Trial to Evaluate a Novel Selective and Reversible Intravenous and Oral P2Y12 Inhibitor Elinogrel Versus Clopidogrel in Patients Undergoing Nonurgent Percutaneous Coronary Intervention: The INNOVATE-PCI Trial. Circ Cardiovasc Interv 2012; 5: 336-46.
37. Shinohara Y, Nishimaru K, Sawada T, for S-ACCESS Study Group. Sarpogrelate-SarpoAspirin comparative clinical study for efficacy and safety in secondary prevention of cerebral infarction (S-ACCESS): a randomized, double-blind, aspirin controlled trial. Stroke 2008; 39: 1827-33.
38. Brass LF. Thrombin and platelet activation. Chest 2003; 124 (Suppl 3): 18S-25S.
39. Becker RC, Moliterno DJ, Jennings LK, et al. Safety and tolerability of SCH 530348 in patients undergoing non-urgent percutaneous coronary intervention: a randomised, double-blind, placebocontrolled phase II study. Lancet 2009; 373: 919-28.
40. Goto S, Ogawa H, Takeuchi M, et al; J-LANCELOT (Japanese-Lesson from Antagonizing the Cellular Effect of Thrombin) Investigators. Double-blind, placebo-controlled phase II studies of the protease-activated receptor 1 antagonist E5555 (atopaxar) in Japanese patients with acute coronary syndrome or high-risk coronary artery disease. Eur Heart J 2010; 31: 2601-13.
41. Morrow DA, Scirica BM, Fox KA, et al. Evaluation of a novel antiplatelet agent for secondary prevention in patients with a history of atherosclerotic disease: Design and rationale for the Thrombin-Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events (TRA 2 ° P)-TIMI 50 trial. Am Heart J 2009; 158: 335-41.
42. TRA*CER Executive and Steering Commettees. The thrombin receptor antagonists for clinical event reduction in acute coronary syndrome (TRA*ER) trial: study design and rationale. Am Heart J 2009; 158: 327-47.
43. Van de Werf F. Inhibitors of the platelet thrombin receptor. Will they live up to their promises? Circulation. 2011; 123: 1833-35.
44. O'Donoghue M, Bhatt DL, Wiviott SD, et al. Safety and tolerability of atopaxar in the treatment of patients with acute coronary syndromes. The lessons from antagonizing the cellular effects of thrombin-acute coronary syndromes trial. Circulation 2011; 123: 1843-53.
45. Wiviott SD, Flather MD, O'Donoghue ML, et al. Randomized trial of atopaxar in the treatment of patients with coronary artery disease. The lessons from antagonizing the cellular effect of thrombincoronary artery disease trial. Circulation 2011; 123: 1854-63.
46. Bhatt DL. Intensifying platelet inhibition-navigating between Scylla and Carybdis. N Engl J Med 2007; 357: 2078-81.
47. Siller-Matula JM, Krumphuber J, Jilma B. Pharmacokinetic, pharmacodynamic and clinical profile of novel antiplatelet drugs targeting vascular diseases. Br J Pharmacol 2010; 159: 502-17.
48. Gresele P, Agnelli G. Novel approaches to the treatment of thrombosis. Trends Pharmacol Sci 2002; 23: 25-32.
49. Gresele P, Falcinelli E, Momi S. Potentiation and priming of platelet activation: a potential target for antiplatelet therapy. Trends Pharmacol Sci 2008; 29: 352-60.
50. Sadler JE. Biochemistry and genetics of von Willebrand factor. Annu Rev Biochem 1998; 67: 395-424.
51. Kleinschnitz C, De Meyer SF, Schwarz T, et al. Deficiency of von Willebrand factor protects mice from ischemic stroke. Blood 2009; 113: 3600-03.
52. Zhao BQ, Chauhan AK, Canault M, et al. von Willebrand factorcleaving protease ADAMTS13 reduces ischemic brain injury in experimental stroke. Blood 2009; 114: 3329-34.
53. De Meyer SF, Deckmyn H, Vanhoorelbeke K. von Willebrand factor to the rescue. Blood 2009; 113: 5049-57.
54. Gresele P, Momi S. Inhibitors of the interaction between von willebrand factor and GPIb/IX/V. Handb Exp Pharmacol 2012; 210: 287-309.
55. Kageyama S, Yamamoto H, Nakazawa J, et al. Pharmacokinetics and pharmacodynamics of AJW200, a humanized monoclonal antibody to von Willebrand factor, in monkey. Arterioscler Thromb Vasc Biol 2002; 22: 187-92.
56. Fontayne A, Meiring M, Lamprecht S, et al. The humanized antiglycoprotein Ib monoclonal antibody h6B4-Fab is a potent and safe antithrombotic in a high shear arterial thrombosis model in baboons. Thromb Haemost 2008; 100: 670-77.
57. Kageyama S, Matsushita J, Yamamoto H. Effect of a humanized monoclonal antibody to von Willebrand factor in a canine model of coronary arterial thrombosis. Eur J Pharmacol 2002; 443: 143-49.
58. Yamashita A, Asasda Y, Sugimura H, et al. Contribution of von Willebrand factor to thrombus formation on neointima of rabbits stenotic iliac artery under high blood-flow velocity. Arterioscler Thromb Vasc Biol 2003; 23: 1105-10.
59. Spiel AO, Mayr FB, Ladani N, et al. The aptamer ARC1779 is a potent and specific inhibitor of von Willebrand factor mediated ex vivo platelet function in acute myocardial infarction. Platelets 2009; 20: 334-40.
60. Gilbert JC, DeFeo-Fraulini T, Hutabarat RM, et al. First-in-human evaluation of anti von Willebrand factor therapeutic aptamer ARC1779 in healthy volunteers. Circulation 2007; 116: 2678-86.
61. Jilma B, Paulinska P, Jilma-Stohlawetz P, et al. A randomized pilot trial of the anti-von Willebrand factor aptamer ARC1779 in patients with type 2B von Willebrand disease. Thromb Haemost 2010; 104: 563-70.
62. Jilma-Stohlawetz P, Gilbert JC, Gorczyca ME, et al. A dose ranging phase I/II trial of the von Willebrand factor inhibiting aptamer ARC1779 in patients with congenital thrombotic thrombocytopenic purpura. Thromb Haemost 2011; 106: 539-47.
63. Markus HS, McCollum C, Imray C, et al. The von Willebrand inhibitor ARC1779 reduces cerebral embolization after carotid endarterectomy-A randomized trial. Stroke 2011; 42: 2149-53.
64. Van Bockenstaele F, Holz JB, Revets H. The development of nanobodies for therapeutic applications. Curr Opin Invest Drugs 2009; 10: 1212-24.
65. Ulrichts H, Silence K, Schoolmester A, et al. Antithrombotic drug candidate ALX-0081 shows superior preclinical efficacy and safety compared to currently marketed antiplatelet drugs. Blood 2011; 118: 757-65.
66. Deckmyn H, De Meyer SF, Broos K, et al. Inhibitors of the interactions between collagen and its receptors on platelets. Handb Exp Pharmacol 2012; 210: 311-37.
67. Jandrot-Perrus M, Busfield S, Lagrue AH, et al. Cloning, characterization, and functional studies of human and mouse glycoprotein VI: a platelet-specific collagen receptor from the immunoglobulin superfamily. Blood 2000; 96: 1798-807.
68. Bigalke B, Lindemann S, Ehlers R, et al. Expression of platelet collagen receptor glycoprotein VI is associated with acute coronary syndrome. Eur Heart J 2006; 27: 2165-69.
69. Bigalke B, Stellos K, Geisler T, et al. Expression of platelet glycoprotein VI is associated with transient ischemic attack and stroke. Eur J Neurol 2010; 17: 111-7.
70. Bigalke B, Stellos K, Geisler T, et al. Glycoprotein VI as a prognostic biomarker for cardiovascular death in patients with symptomatic coronary artery disease. Clin Res Cardiol 2010; 99: 227-33.
71. Joutsi-Korhonen L, Smethurst PA, Rankin A, et al. The lowfrequency allele of the platelet collagen signaling receptor glycoprotein VI is associated with reduced functional responses and expression. Blood 2003; 101: 4372-79.
72. Ollikainen E, Mikkelsson J, Perola M, et al. Platelet membrane collagen receptor glycoprotein VI polymorphism is associated with coronary thrombosis and fatal myocardial infarction in middle-aged men. Atherosclerosis 2004; 176: 95-9.
73. Arthur JF, Dunkley S, Andrews RK. Platelet glycoprotein VIrelated clinical defects. Br J Haematol 2007; 139: 363-72.
74. Nieswandt B, Schulte V, Bergmeier W, et al. Long-term antithrombotic protection by in vivo depletion of platelet glycoprotein VI in mice. J Exp Med 2001; 193: 459-69.
75. Schulte V, Reusch HP, Pozgajova M, et al. Two-phase antithrombotic protection after anti-glycoprotein VI treatment in mice. Arterioscler Thromb Vasc Biol 2006; 26: 1640-47.
76. Matsumoto Y, Takizawa H, Nakama K, et al. Ex vivo evaluation of anti-GPVI antibody in cynomolgus monkeys: dissociation between anti-platelet aggregatory effect and bleeding time. Thromb Haemost 2006; 96: 167-75.
77. Li H, Lockyer S, Concepcion A, et al. The Fab fragment of a novel anti-GPVI monoclonal antibody, OM4, reduces in vivo thrombosis without bleeding risk in rats. Arterioscler Thromb Vasc Biol 2007; 27: 1199-05.
78. Takayama H, Hosaka Y, Nakayama K, et al. A novel antiplatelet antibody therapy that induces cAMP-dependent endocytosis of the GPVI/Fc receptor gamma-chain complex. J Clin Invest 2008; 118: 1785-95.
79. Massberg S, Konrad I, Bultmann A, et al. Soluble glycoprotein VI dimer inhibits platelet adhesion and aggregation to the injured vessel wall in vivo. FASEB J 2004; 18: 397-9.
80. Takayama H, Hosaka Y, Nakayama K, et al. A novel antiplatelet antibody therapy that induces cAMP-dependent endocytosis of the GPVI/Fc receptor gamma-chain complex. J Clin Invest 2008; 118: 1785-95.
81. Ungerer M, Rosport K, Bültmann A, et al. Novel Antiplatelet Drug Revacept (Dimeric Glycoprotein VI-Fc) Specifically and Efficiently Inhibited Collagen-Induced Platelet Aggregation Without Affecting General Hemostasis in Humans. Circulation 2011; 123: 1891-9.
82. Ogihara Y, Muramatsu1 S, Kaneda1 Y, et al. Pharmacological Profile of DZ-697b, a Novel Anti-Platelet Agent-Selective Inhibitor of VWF-and Collagen-Induced Platelet Aggregation. Blood 2005; 106: 1875.
83. Shibutani T, Iijima1 T, Kaneda Y, et al. Anti-Thrombotic Action of DZ-697b, a Novel Anti-Platelet Agent, on Photochemically Induced Thrombosis with Lower Bleeding Risk in Guinea Pigs. Blood 2005; 106: 1870.
84. Zafar MU, Ibanez B, Choi BG, et al. A new oral antiplatelet agent with potent antithrombotic properties: comparison of DZ-697b with clopidogrel a randomised phase I study. Thromb Haemost 2010; 103: 205-12.
85. Libby P, Simon DI. Inflammation and thrombosis: the clot thickens. Circulation. 2001; 103: 1718-20.
86. Riccaboni M, Bianchi I, Petrillo P. Spleen tyrosine kinases: biology, therapeutic targets and drugs. Drug Discov Today 2010; 15: 517-30.
87. Zafar MU, Ibanez B, Choi BG, et al. A new oral antiplatelet agent with potent antithrombotic properties: comparison of DZ-697b with clopidogrel a randomised phase I study. Thromb Haemost 2010; 103: 205-12.
88. Andre P, Morooka T, Sim D, et al. Critical role for Syk in responses to vascular injury. Blood 2011; 118: 5000-10.
89. Hilgendorf I, Eisele S, Remer I, et al. The Oral Spleen Tyrosine Kinase Inhibitor Fostamatinib Attenuates Inflammation and Atherogenesis in Low-Density Lipoprotein Receptor-Deficient Mice. Arterioscler Thromb Vasc Biol 2011; 31: 1991-9.
90. Podolanczuk A, Lazarus AH, Crow AR, et al. Of mice and men: an open-label pilot study for treatment of immune thrombocytopenic purpura by an inhibitor of Syk. Blood 2009; 113: 3154-60.
91. Mochly-Rosen D, Khaner H, Lopez J, et al. Intracellular receptors for activated protein kinase C: identification of a binding site for the enzyme. J Biol Chem 1991; 266: 14866-8.
92. Chen L, Hahn H, Wu G, et al. Opposing cardioprotective actions and parallel hypertrophic effects of δ and ε PKC. Proc Natl Acad Sci USA 2001; 98: 11114-9.
93. Inagaki K, Chen L, Ikeno F, et al. Inhibition of β-protein kinase C protects against reperfusion injury of the ischemic heart in vivo. Circulation 2003; 108: 2304-07.
94. Ikeno F, Inagaki K, Rezaee M, et al. Impaired perfusion after myocardial infarction is due to reperfusion-induced βPKC-mediated myocardial damage. Cardiovasc Res 2007; 73: 699-709.
95. (DELTA MI) Investigators, Bates E, Bode C, Costa M, et al. Direct Inhibition of delta-Protein Kinase C Enzyme to Limit Total Infarct Size in Acute Myocardial Infarction Intracoronary KAI-9803 as an adjunct to primary percutaneous coronary intervention for acute ST-segment elevation myocardial infarction. Circulation 2008; 117: 886-96.
96. Vanhaesebroeck B, Waterfield MD. Signaling by distinct classes of phosphoinositide 3-kinases. Exp Cell Res 1999; 253: 239-54.
97. Hirsch E, Braccini L, Ciraolo E, et al. Twice upon a time: PI3K's secret double life exposed. Trends Biochem Sci. 2009; 34: 244-48.
98. Jackson SP, Schoenwaelder SM, Goncalves I, et al. PI 3-kinase p110β: a new target for antithrombotic therapy. Nat Med 2005; 11: 507-14.
99. Hirsch E., Bosco O, Tropel P, et al. Resistance to thromboembolism in PI3Kγ-deficient mice. FASEB J 2001; 15: 2019-21.
100. Mega JL. A new era for anticoagulation in atrial fibrillation. N Engl J Med 2011; 365: 1052-4.